1373503-45-7

Usage

Uses

Used in Medicinal Chemistry:
Tert-butyl 4-((benzyloxycarbonylamino)methyl)-3,3-difluoropiperidine-1-carboxylate is used as a building block in the synthesis of various pharmaceutical compounds due to its unique structure and functional groups.
Used in Drug Synthesis:
tert-butyl 4-((benzyloxycarbonylaMino)Methyl)-3,3-difluoropiperidine-1-carboxylate is utilized as an intermediate in the development of new drugs, particularly in the field of medicinal chemistry, owing to its potential pharmaceutical or biological activity.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-butyl 4-((benzyloxycarbonylamino)methyl)-3,3-difluoropiperidine-1-carboxylate is used as a key component in the formulation of drugs, leveraging its unique structural features and functional groups to enhance drug efficacy and properties.

Upstream product

• 100-51-6 benzyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1373503-54-8 (R)-2-(1-(tert-butoxycarbonyl)-3,3-difluoropiperidin-4-yl)acetic acid 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 
• 1373503-54-8 (±)-2-(1-( tert-butoxycarbonyl)-3,3-difluoropiperidin-4-yl)acetic acid 
• 1334412-95-1 tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylate 

Downstream Products

• 1303973-22-9 tert-butyl 4-(aminomethyl)-3,3-difluoropiperidine-1-carboxylate 
• 1303973-22-9 (S)-tert-butyl 4-(aminomethyl)-3,3-difluoropiperidine-1-carboxylate 

Relevant academic research and scientific papers

TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

1-R 1 -3, 3-difluoro-4-R 2-piperidine and its derivatives preparation method

The invention relates to a preparation method for 1-R1-3,3-difluoro-4-R2-piperidine shown as a formula (I) and derivatives thereof. In the formula (I), R1 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R4 is C1-C9 alkyl, aryl or benzyl; R5 is C1-C9 alkyl, aryl or benzyl; R2 is CH2NHR6 or CH2CO2H; R6 is hydrogen, C1-C9 alkyl, aryl, benzyl, CF3CO, R4CO or R5OCO; R3 is hydrogen, C1-C9 alkyl, aryl or benzyl; and the above optional groups are not substituted or substituted by a substituted group consisting of one or more of alkyl, haloalkyl, hydroxyalkyl, halogen, alkyloxy or hydroxyl. The preparation method is characterized by comprising steps shown by a reaction formula in the specification.